基线HBcrAg联合治疗结束时HBsAg预测恩替卡韦或替诺福韦停药后HBV复发
本研究纳入治疗结束时HBsAg<100 IU/mL的慢性乙型肝炎患者,高雄组190例为开发组、林口组188例为验证组。开发组中108例HBsAg≤40 IU/mL者分析显示,年龄、核苷(酸)类似物经治状态、基线HBcrAg及治疗结束时HBsAg独立与病毒学和临床复发相关。治疗结束时HBsAg≤20 IU/mL为最佳截断值,基线HBcrAg≤4 log U/mL且治疗结束时HBsAg≤20 IU/mL者5年病毒学复发率6.5%、临床复发率0%、HBsAg清除率81.7%。
要点
- 治疗结束时HBsAg≤20 IU/mL为最小化HBV复发的最佳截断值。
- 基线HBcrAg≤4 log U/mL联合治疗结束时HBsAg≤20 IU/mL者复发风险低。
- 该联合指标可能有助于核苷(酸)类似物停药后随访策略。
核心结论
- 基线HBcrAg≤4 log U/mL联合治疗结束时HBsAg≤20 IU/mL可能降低HBV复发风险并提高HBsAg清除率,可能有助于核苷(酸)类似物停药后随访策略。
研究设计与样本
- 研究纳入治疗结束时HBsAg<100 IU/mL的慢性乙型肝炎患者,高雄长庚纪念医院190例为开发组,林口长庚纪念医院188例为验证组。
- 开发组中108例治疗结束时HBsAg≤40 IU/mL的患者用于分析HBV复发和HBsAg清除的预测因素。
主要发现
- 多因素分析显示年龄、核苷(酸)类似物经治状态、基线HBcrAg和治疗结束时HBsAg独立与病毒学和临床复发相关。
- 开发组和验证组中,治疗结束时HBsAg≤20 IU/mL者的病毒学和临床复发率低于治疗结束时HBsAg 21-40 IU/mL者和HBsAg 41-100 IU/mL者,HBsAg清除率高于后两组。
- 开发组中基线HBcrAg≤4 log U/mL且治疗结束时HBsAg≤20 IU/mL者的5年病毒学复发率为6.5%、临床复发率为0%、HBsAg清除率为81.7%。
关键数值与推荐
- 治疗结束时HBsAg 20 IU/mL为最小化HBV复发的最佳截断值。
- 基线HBcrAg≤4 log U/mL且治疗结束时HBsAg≤20 IU/mL者5年病毒学复发率6.5%、临床复发率0%、HBsAg清除率81.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with chronic hepatitis B (CHB), the optimal stopping criteria for entecavir or tenofovir disoproxil fumarate treatment remain unclear. METHODS: This study recruited CHB patients with levels of hepatitis B surface antigen (HBsAg) <100 IU/mL at the end of treatment (EOT) from Kaohsiung (n = 190) and Linkou (n = 188) Chang Gung Memorial Hospitals for use as development and validation groups, respectively. RESULTS: In the development group, 108 patients with HBsAg ≤40 IU/mL were used for analysis of predictors of HBV relapse and HBsAg loss. Multivariate analysis showed that age, nucleos(t)ide analogue (NA)-experienced status, baseline hepatitis B core-related antigen (HBcrAg) and HBsAg at EOT were associated independently with virological and clinical relapse. An HBsAg level of 20 IU/mL at EOT was the best cut-off value for minimizing HBV relapse. Patients with EOT HBsAg ≤20 IU/mL had lower virological and clinical relapse rates and higher HBsAg loss rates than those with EOT HBsAg 21-40 IU/mL and HBsAg 41-100 IU/mL in the development and validation groups. The virological and clinical relapse rates were very low (5-year rates: 6.5% and 0%, respectively) and HBsAg loss rate was very high (5-year rate: 81.7%) in patients with a combination of baseline HBcrAg ≤4 log U/mL and EOT HBsAg ≤20 IU/mL in the development group. CONCLUSIONS: A combination of baseline HBcrAg ≤4 log U/mL and EOT HBsAg level ≤20 IU/mL might reduce the risk of HBV relapse and increase HBsAg loss rate, and might be helpful for off-NA follow-up strategy.
引用
- Tseng TN, Jeng WJ, Hu TH, et al. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. J Antimicrob Chemother. 2023. PMID: 36478233. doi:10.1093/jac/dkac409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。